Holding(s) in Company
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
|
|
|
|||
1. Identity of the issuer or the underlying issuer |
Verona Pharma PLC |
|||
2 Reason for the notification (please tick the appropriate box or boxes): |
||||
An acquisition or disposal of voting rights |
|
|||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
|
|||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|
|||
An event changing the breakdown of voting rights |
|
|||
Other (please specify): Change to notifiable interest following share issue |
|
X |
||
3. Full name of person(s) subject to the |
OrbiMed Private Investments VI, LP |
|||
4. Full name of shareholder(s) |
|
|||
5. Date of the transaction and date on |
May 19, 2017 |
|||
6. Date on which issuer notified: |
May 23, 2017 |
|||
7. Threshold(s) that is/are crossed or |
Downward crossing of the 10% threshold |
|||
8. Notified details: |
||||||||||||||||
A: Voting rights attached to shares viii, ix |
||||||||||||||||
Class/type of
|
Situation previous |
Resulting situation after the triggering transaction |
||||||||||||||
Number |
Number |
Number |
Number of voting |
% of voting rights x |
||||||||||||
Direct |
Direct xi |
Indirect xii |
Direct |
Indirect |
||||||||||||
|
4,669,847 |
4,669,847 |
4,669,847 |
4,669,847 |
0 |
4.47% |
0 |
|||||||||
GB00B06GSH43 |
||||||||||||||||
US9250501064 |
5,333,328 |
5,333,328 |
5,333,328 |
5,333,328 |
0 |
5.10% |
0 |
|||||||||
|
||||||||||||||||
B: Qualifying Financial Instruments |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting |
||||||||||||
|
|
|
|
|
||||||||||||
|
||||||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial |
Exercise price |
Expiration date xvii |
Exercise/ |
Number of voting rights instrument refers to
|
% of voting rights xix, xx
|
|||||||||||
|
|
|
|
|
Nominal |
Delta |
||||||||||
|
|
|||||||||||||||
|
||||||||||||||||
Total (A+B+C) |
||||||||||||||||
Number of voting rights |
Percentage of voting rights |
|||||||||||||||
10,003,175 |
9.57% |
|||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or the |
||
These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the sole general partner of OPI VI, and OrbiMed Advisors LLC ("Advisors"), is the sole managing member of GP VI. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of, and holder of a controlling interest in, Advisors. |
||
|
||
Proxy Voting: |
||
10. Name of the proxy holder: |
|
|
11. Number of voting rights proxy holder will cease to hold: |
|
|
12. Date on which proxy holder will cease to hold voting rights: |
|
|
|
||
|
|
|
14. Contact name: |
Douglas Coon |
|
15. Contact telephone number: |
212-739-6400 |
|
This information is provided by RNS